InProTher announces EUR 6MSeed financing with the participation of the European Innovation Council Fund to develop first-in-class cancer immunotherapy

Download PDF version here • Danish start-up developing immunotherapies designed to fight the tumors from within • Financing supports GMP and tox studies and will advance InProTher’s first-in-class cancer immunotherapy into First-in-Human clinical trials • Strengthens team with appointment of industry heavyweights Dr. Sven Rohman as Chairman and Dr. Hamina Patel as CMO Copenhagen, Denmark, 24 May 2023: InProTher, an early-stage biotechnologycompany developing effective immunotherapies targeting the Human Endogenous Retroviruses (HERVs), today announces that it has raised EUR 6M of Seed funding from private investors with the participation of the European Innovation Council (EIC) Fund. The financing will […]

InProTher announces the appointment of Jordi Naval as CEO, along with angel investment funding

Copenhagen, February 15th 2021 InProTher Aps, a biotechnology company focused on developing breakthrough strategies for Immuno-oncology based on a new target class of endogenous retroviruses, today announced that it has appointed Jordi Naval as chief executive officer, along with undisclosed angel investment funding from Peter Elbæk and Johnny Henriksen. Naval is an accomplished biotech CEO […]

Dr. Martin Gleave joins InProTher as scientific advisor

InProTher is pleased to announce a new, exciting collaboration with Dr. Martin Gleave who joins the company as a scientific advisor. Dr. Gleave is a urologic surgeon and Distinguished Professor and Chair of the Department of Urologic Sciences at University of British Columbia, Canada. He is also co-founder and Executive Director of the highly respected […]

Postdoctoral grant allows InProTher to engage in new exciting collaborations

Following the recruitment of Emeline Ragonnaud, who joined the team from NIH in June this year, InProTher is now delighted to announce the award of a postdoctoral grant from Innovation Fund Denmark for her project.  The grant has a 3-year perspective and allows InProTher to establish strategic collaborations with key people within each of their […]

CEO at SIRION, Christian Thirion, joins InProTher as a Board Member

InProTher is pleased to welcome Christian O. Thirion, Ph.D., who has joined the Board of Directors in February 2020. Christian is the founder and CEO of SIRION Biotech GmbH, a company that InProTher recently entered into a partnership with. At SIRION, he has held multiple leadership positions and has been responsible for the scientific direction […]

Former F-star CEO joins InProTher as strategic advisor

InProTher can proudly welcome John Haurum, M.D., Ph.D. as a strategic advisor. John Haurum is a Non-executive Director in various European biotech companies, i.e. Synklino, Neophore, and Synact. From 2012 – 2018, Haurum was the CEO of F-star in Cambridge, UK, where he built a successful biotech company that initiated two clinical trials in oncology […]

SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)

SIRION Biotech Licenses Adenovirus Technology to Danish Startup, InProTher for its Novel Immunotherapy Design Targeting Endogenous Retrovirus (ERV)

MUNICH & COPENHAGEN, February 4, 2020— SIRION Biotech GmbH (“SIRION”), a world leader in viral vector-based gene delivery technologies for gene and cell therapy, and InProTher Aps (“InProTher”), a Danish start up supported by Novo Nordisk Foundation’s BioInnovation Institute (BII), today announced a broad licensing agreement which includes coverage of SIRION’s adenovirus technologies to cancer […]